IL4 and serum lipopolysaccharide activity: The study further demonstrated that IL-4 nanotherapy resolved immunoparalysis in mice with lipopolysaccharide-induced hyperinflammation, as well as in ex vivo human sepsis models and in experimental endotoxemia.